Clinical Trial Update: Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of orelabrutinib, lisaftoclax, and rituximab in untreated, high-risk Mantle Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Lisaftoclax (APG-2575)
• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Mantle Cell Lymphoma (MCL) | Phase 2 | Status: RECRUITING